Measurement of abdominal symptoms by validated questionnaire: a 3‐month recall timeframe as recommended by Rome III is not superior to a 1‐year recall timeframe

Aliment Pharmacol Ther 31, 1237–1247 Summary Background  Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3‐month recall time for symptoms, rather than 1‐year. Aim  To validate a new version of the Talley‐Bowel Disease Questionnaire (Talley‐BDQ)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2010-06, Vol.31 (11), p.1237-1247
Hauptverfasser: REY, E., LOCKE, G. R., JUNG, H.‐K., MALHOTRA, A., CHOUNG, R. S., BEEBE, T. J., SCHLECK, C. D., ZINSMEISTER, A. R., TALLEY, N. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aliment Pharmacol Ther 31, 1237–1247 Summary Background  Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3‐month recall time for symptoms, rather than 1‐year. Aim  To validate a new version of the Talley‐Bowel Disease Questionnaire (Talley‐BDQ) and assess the impact of recall time period on the prevalence of symptoms. Methods  A sample of community residents were randomly mailed a survey using 1‐year (n = 396) or 3‐month recall period (n = 374). We evaluated the reliability and the concurrent validity of the two versions of the questionnaire. The proportions of subjects reporting symptoms in the two versions were compared. Results  The median (IQR) kappa on symptom‐related questions was 0.70 (0.57–0.76) from the 1‐year version and 0.66 (0.56–0.77) from the 3‐month version. A median kappa of 0.39 (0.19–0.70) and 0.58 (0.39–0.73) was observed for concurrent validation of the 1‐year and 3‐month versions respectively. Except for gastro‐oesophageal reflux symptoms, no differences were observed on the prevalence of clinically relevant symptoms. Conclusion  The revised Talley‐BDQ is reliable, with excellent reproducibility and validity. There were few differences in reported symptom rates between the 3‐month and 1‐year recall time versions of the questionnaire. A 1‐year recall time may more efficiently capture infrequent or subtle symptoms.
ISSN:0269-2813
1365-2036
DOI:10.1111/j.1365-2036.2010.04288.x